Article
Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis
6 Jun 2013
Abstract excerpt
Resting tumor cells represent a huge challenge during anticancer therapy due to their increased treatment resistance. TNF-related apoptosis-inducing ligand (TRAIL) is a putative future anticancer drug, currently in phases I and II clinical studies. We recently showed that TRAIL is able to target leukemia stem cell surrogates. Here, we tested the ability of TRAIL to target cell cycle-arrested tumor cells. Cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
